Ardelyx Has Big Potential

The biotech sector has made a big push over the past three weeks and has been one of the top performing areas of the market over that time. Large-cap concerns have a nice run, perhaps as the market finally woke up to the fact that as a collective they were selling at their cheapest valuations since 2011. This is also one of the few industries in the S&P 500 that is cranking out revenue and earnings growth right now, in a very challenging global backdrop.

The small and mid-cap areas of the market have also participated in this broad-based rally. These names have been helped tremendously by the pickup in M&A activity in recently weeks, which have seen the likes of Anacor Pharmaceuticals (ANAC), Xenoport (XNPT) and Celator Pharmaceuticals (CPXX) being acquired for premiums of between around 60% to approximately 80%....394 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.